Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784212 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNATLR2ADRB2ADRB1 | |
| Glycerol Phenylbutyrate SCHEMBL10102804 | 0.93 | ADRB2 (0.56) | ALDH1A1LMNATLR2ADRB2ADRB1 | |
| SCHEMBL27665720 | 0.90 | ALDH1A1 (0.69) | ALDH1A1LMNATLR2LPAR1MGLL | |
| SCHEMBL13901108 | 0.87 | ALDH1A1 (0.54) | ALDH1A1LMNATLR2LPAR1PRKCA | |
| SCHEMBL15061844 | 0.86 | MGLL (0.61) | TLR2ADRB2ADRB1ADRB3ALOX5 | |
| SCHEMBL406382 | 0.84 | ALOX5 (0.59) | LMNAADRB2ADRB1ADRB3ALOX5 | |
| SCHEMBL18618733 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNATLR2LPAR1PRKCA | |
| SCHEMBL18227895 | 0.83 | NR1I2 (0.52) | ALDH1A1TLR2ADRB2ADRB1ADRB3 | |
| SCHEMBL18174526 | 0.83 | NR1I2 (0.52) | ALDH1A1TLR2ADRB2ADRB1ADRB3 | |
| SCHEMBL15061850 | 0.83 | ADRB2 (0.53) | TLR2ADRB2ADRB1ADRB3ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258047-A1 | Therapeutic Compounds | AKTHELIA PHARMACEUTICALS (IS) | 2015-09-17 | — | — | US | disclosed |
| US-9078864-B2 | Agonists for antimicrobial peptide systems | AKTHELIA PHARMACEUTICALS (IS) | 2015-07-14 | — | — | US | disclosed |
| US-20140155358-A1 | Therapeutic Compounds | AKTHELIA PHARMACEUTICALS (IS) | 2014-06-05 | — | — | US | disclosed |
| US-20110118217-A1 | Agonists for Antimicrobial Peptide Systems | AKTHELIA PHARMACEUTICALS (IS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118217-A1 | Agonists for Antimicrobial Peptide Systems | VIP, GLP1R, MAVS | ALDH1A1 3865/4885LMNA 4038/4885TLR2 58/4885 |
| US-20150258047-A1 | Therapeutic Compounds | VIP, CFTR, ATF1 | ALDH1A1 2247/4885LMNA 4633/4885TLR2 38/4885 |
| US-20140155358-A1 | Therapeutic Compounds | VIP, CFTR, GABBR1 | ALDH1A1 3159/4885LMNA 4425/4885TLR2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.